CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRMD CorMedix Inc.

Market Closed 12-12 16:00:00 EST

11.49

-0.25

-2.13%

盘后11.71

+0.22+1.91%

19:56 EST

High11.91	Low11.49	Vol3.55M
Open11.91	D1 Closing11.74	Amplitude3.58%
Mkt Cap905.29M	Tradable Cap846.75M	Total Shares78.79M
T/O41.55M	T/O Rate4.82%	Tradable Shares73.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRMD","market":"US","secType":"STK","nameCN":"CorMedix Inc.","latestPrice":11.49,"timestamp":1765573200000,"preClose":11.74,"halted":0,"volume":3554836,"hourTrading":{"tag":"盘后","latestPrice":11.71,"preClose":11.49,"latestTime":"19:56 EST","volume":34470,"amount":396093.7658,"timestamp":1765587407423},"delay":0,"floatShares":73694900,"shares":78789045,"eps":2.252104,"marketStatus":"Market Closed","change":-0.25,"latestTime":"12-12 16:00:00 EST","open":11.91,"high":11.91,"low":11.49,"amount":41545727.370436,"amplitude":0.035775,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.252104,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1273723200000,"exchange":"NASDAQ","adjPreClose":11.74,"preHourTrading":{"tag":"盘前","latestPrice":11.74,"preClose":11.74,"latestTime":"08:54 EST","volume":3000,"amount":35124.69,"timestamp":1765547687507},"postHourTrading":{"tag":"盘后","latestPrice":11.71,"preClose":11.49,"latestTime":"19:56 EST","volume":34470,"amount":396093.7658,"timestamp":1765587407423},"volumeRatio":0.980961979870641,"impliedVol":0.7308,"impliedVolPercentile":0.48},"requestUrl":"/m/hq/s/CRMD","defaultTab":"news","newsList":[{"id":"2590456808","title":"CorMedix Director Steven W. Lefkowitz Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590456808","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590456808?lang=en_us&edition=fundamental","pubTime":"2025-12-11 10:39","pubTimestamp":1765420767,"startTime":"0","endTime":"0","summary":"Steven W. Lefkowitz, Director of CorMedix Inc., reported a disposal of common shares of CorMedix Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL83jNQn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"CorMedix Director Steven W. Lefkowitz Reports Sale of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2585066170","title":"Assessing CorMedix (CRMD) Valuation Following Recent Share Price Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2585066170","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585066170?lang=en_us&edition=fundamental","pubTime":"2025-11-23 00:24","pubTimestamp":1763828649,"startTime":"0","endTime":"0","summary":"CorMedix (CRMD) shares have seen activity recently, with investors keeping a close eye on its latest movements and company performance. Over the past month, the stock is down 14%; however, year-to-date it remains up by 18%.\nSee our latest analysis for CorMedix.\nDespite a steep drop over the last month, CorMedix's 2024 share price return still suggests that investors are weighing long-term growth against recent volatility. While momentum has faded in recent weeks, the three-year total...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/assessing-cormedix-crmd-valuation-following-recent-share-pri","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/assessing-cormedix-crmd-valuation-following-recent-share-pri","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2583569053","title":"CorMedix price target raised to $18 from $17 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2583569053","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583569053?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:10","pubTimestamp":1763032243,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on CorMedix (CRMD) to $18 from $17 and keeps a Buy rating on the shares post ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cormedix-price-target-raised-to-18-from-17-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cormedix-price-target-raised-to-18-from-17-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2583855979","title":"U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2583855979","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583855979?lang=en_us&edition=fundamental","pubTime":"2025-11-13 15:46","pubTimestamp":1763019995,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare Nov 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.listed companies, in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL4N3WP0H3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTCI","KRRO","CRMD","BMY","LCID","KBDC","BCSF","ORKA","AKAM","KMI","MRK","BK4020","VAC","GFS","PRVA","LPRO","NXT","LU2417539215.USD","CCOI","CELC","LU1221951129.SGD","AMGN","HTFL","ALB","LU1880398471.USD","ABBV","GLXY","HHH","AMN","ANAB","CSCO","LU2361045086.USD","LWAY","BRBR","JNJ","LU1046421795.USD","CVX","BK4534","LEGN","LU1221951046.USD","LU1974910355.USD","PCH","DHC","LU0868494617.USD","LU0823416689.USD","GILD"],"gpt_icon":1},{"id":"2583045588","title":"Talphera Raises $17 Million in Private Placement Led by CorMedix","url":"https://stock-news.laohu8.com/highlight/detail?id=2583045588","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583045588?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:15","pubTimestamp":1762982107,"startTime":"0","endTime":"0","summary":"Talphera Inc. has announced the closing of the first tranche of a private placement financing, raising $17 million as part of a two-tranche deal for up to $29 million. The financing round was led by CorMedix, Inc. and included participation from existing investors Nantahala Capital, Rosalind Advisors, Rock Springs Capital, as well as new institutional investors. The second tranche is contingent on Talphera's stock price reaching or exceeding $0.6875 for five consecutive days following the achievement of the primary endpoint in the NEPHRO CRRT study, though investors may waive this condition. In addition, certain purchasers have already waived conditions to enable further closings, resulting in additional gross proceeds of approximately $1.6 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL8dNj71:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007","TLPH"],"gpt_icon":0},{"id":"2583203588","title":"Talphera Reports Third Quarter 2025 Results and Announces $17 Million Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583203588","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583203588?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:09","pubTimestamp":1762981795,"startTime":"0","endTime":"0","summary":"Talphera Inc. announced its third quarter 2025 financial results and provided a corporate update. As of September 30, 2025, the company reported cash and investments totaling $21.3 million. In September, Talphera closed the first tranche of a two-part private placement financing, raising $17 million, with a second tranche of up to $12 million pending based on certain stock price and clinical study milestones. The financing was led by CorMedix, Inc. and included participation from existing and new institutional investors. Talphera stated it expects its current cash position, together with future financing tranches, to be sufficient through a potential PMA approval of Niyad in late 2026. The company also announced that five of nine target profile clinical study sites for the NEPHRO study are now activated, with study completion expected in the first half of 2026. Four additional sites are expected to be activated in the fourth quarter of 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL1gNfB7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD","TLPH"],"gpt_icon":0},{"id":"2583472304","title":"CorMedix Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2583472304","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583472304?lang=en_us&edition=fundamental","pubTime":"2025-11-13 03:10","pubTimestamp":1762974600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2025 14:10 ET (19:10 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2582303647","title":"BUZZ-U.S. STOCKS ON THE MOVE-Floor & Decor, Starbucks, gold miners","url":"https://stock-news.laohu8.com/highlight/detail?id=2582303647","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582303647?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:56","pubTimestamp":1762962963,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Floor & Decor, Starbucks, gold minersEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslett","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL6N3WO0T2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XOM","LU0096364046.USD","LU0788109394.HKD","BKR","PBF","YTRA","LU2552382132.HKD","MBRX","BROS","CREX","LWAY","ARCO","CWAN","CRMD","LU0795875086.SGD","T","LU0278409577.USD","COGT","LU0823421333.USD","ARTV","NEM","VG","LEGN","LU2471134879.HKD","IBM","LU0882574055.USD","LU0823421416.USD","VVX","FLNG","CRWS","SBUX","KGS","LU2471134523.USD","LU1223082196.USD","LU0208291251.USD","ALKS","BK4179","BHF","LCID","LB","BHVN","AMD","FND","CVX","FTCI","BBWI","VLN"],"gpt_icon":1},{"id":"1116951915","title":"Stock Track | CorMedix Soars 12.60% on Strong Q3 Results and Raised 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1116951915","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116951915?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:02","pubTimestamp":1762959761,"startTime":"0","endTime":"0","summary":"CorMedix Inc. (CRMD) shares surged 12.60% in Wednesday's intraday trading session following the release of its impressive third-quarter 2025 financial results and an upward revision of its full-year...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CRMD"],"gpt_icon":0},{"id":"2582416377","title":"CorMedix Shares Reverse Premarket Course, Last Down 1.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582416377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582416377?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:34","pubTimestamp":1762958060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL4N3WO118:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2582727653","title":"BUZZ-U.S. STOCKS ON THE MOVE-ExxonMobil, Yatra, Venture Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2582727653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582727653?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:13","pubTimestamp":1762956792,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-ExxonMobil, Yatra, Venture GlobalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL6N3WO0IC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KGS","LU0096364046.USD","LU2458330243.SGD","IBM","LU0300736492.USD","ARCO","LU0795875086.SGD","LU0823434740.USD","LU2471134523.USD","VLN","LCID","LU0278409577.USD","CWAN","VVX","BBWI","LU2552382132.HKD","LU2750360997.AUD","LU0882574055.USD","ARTV","SG9999015945.SGD","BHVN","LU2750360641.GBP","VG","ALKS","FTCI","LU2471134879.HKD","CREX","FLNG","LU0109394709.USD","LU1883866441.USD","LU0788109394.HKD","CRMD","COGT","CRWS","LU0109392836.USD","YTRA","LU0456854461.SGD","MBRX","XOM","LU0321505868.SGD","LU0823421416.USD","LU0943347566.SGD","LU2471134796.USD","LU0823421333.USD","LU0823434583.USD","LU0354030511.USD","LU2458330169.SGD"],"gpt_icon":1},{"id":"2582038374","title":"UPDATE: Cormedix Q3 Adj. EPS $0.57 Misses $0.65 Estimate. Adj EPS Excludes One-time Tax Benefit $59.7M","url":"https://stock-news.laohu8.com/highlight/detail?id=2582038374","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582038374?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:55","pubTimestamp":1762955713,"startTime":"0","endTime":"0","summary":"UPDATE: Cormedix Q3 Adj. EPS $0.57 Misses $0.65 Estimate. Adj EPS Excludes One-time Tax Benefit $59.7M","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48801909/update-cormedix-q3-adj-eps-0-57-misses-0-65-estimate-adj-eps-excludes-one-time-tax-benefit-59-7m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2582737130","title":"CorMedix Swings to Q3 Profit, Revenue Rises; Lifts Full-Year Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2582737130","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582737130?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:11","pubTimestamp":1762953074,"startTime":"0","endTime":"0","summary":"CorMedix  reported Q3 earnings Wednesday of $1.26 per diluted share, swinging from a loss of $0.05 a year earlier.One analyst polled by FactSet expected $0.95.Revenue for the quarter ended Sept. 30 was $104.3 million, compared with $11.5 million a year earlier. Analysts surveyed by FactSet expected $86 million.For Q4, the company expects net revenue in the range of $115 million to $135 million. Analysts surveyed by FactSet expect $118.8 million.CorMedix said it now expects full-year 2025 pro forma net revenue of $390 million to $410 million, compared with the prior estimate of $375 million. Analysts polled by FactSet expect $283.7 million.CorMedix shares were up more than 6% in recent Wednesday pre-bell activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"1123083935","title":"Stock Track | CorMedix Soars 9.47% Pre-Market on Strong Q3 Results and Raised Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1123083935","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123083935?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:48","pubTimestamp":1762951719,"startTime":"0","endTime":"0","summary":"Shares of CorMedix Inc. (CRMD) surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an upward revision of its full-year...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CRMD"],"gpt_icon":0},{"id":"1180427284","title":"Stock Track | CorMedix Soars 9.47% Pre-Market on Stellar Q3 Results and Raised Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1180427284","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180427284?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:48","pubTimestamp":1762951706,"startTime":"0","endTime":"0","summary":"CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CRMD"],"gpt_icon":0},{"id":"2582376237","title":"Biopharma firm CorMedix's Q3 net income beats expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376237?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:43","pubTimestamp":1762951382,"startTime":"0","endTime":"0","summary":"Biopharma firm CorMedix's Q3 net income beats expectationsOverviewCorMedix Q3 net income of $108.6 mln, beating analyst expectationsAdjusted EPS for Q3 beats consensus, driven by DefenCath salesCompan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0EZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203345920.USD","LU0203347892.USD","BK4585","BK4588","LU0154245756.USD","BK4149","CMI","CRMD","BK4567","LU0154245673.USD","BK4007","BK4533"],"gpt_icon":0},{"id":"2582376646","title":"CorMedix Shares up 6.9% Premarket After FY Revenue Outlook Lift","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376646","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376646?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:36","pubTimestamp":1762950974,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL4N3WO0UW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2582376574","title":"Earnings Flash (CRMD) CorMedix Posts Q3 EPS $1.26, vs. FactSet Est of $0.95","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376574","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376574?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:35","pubTimestamp":1762950901,"startTime":"0","endTime":"0","summary":"Earnings Flash (CRMD) CorMedix Posts Q3 EPS $1.26, vs. FactSet Est of $0.95","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRMD"],"gpt_icon":0},{"id":"2582663376","title":"CorMedix Inc. - Q3 Net Revenue $104.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582663376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582663376?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:30","pubTimestamp":1762950602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX94D28A:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2582376352","title":"CorMedix Q3 Basic EPS USD 1.42","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376352","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376352?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:30","pubTimestamp":1762950602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX94D28A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cormedix.com","stockEarnings":[{"period":"1week","weight":0.0881},{"period":"1month","weight":0.0061},{"period":"3month","weight":-0.1121},{"period":"6month","weight":-0.2109},{"period":"1year","weight":0.3101},{"period":"ytd","weight":0.4185}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.164363},{"month":2,"riseRate":0.533333,"avgChangeRate":0.076401},{"month":3,"riseRate":0.533333,"avgChangeRate":0.047277},{"month":4,"riseRate":0.466667,"avgChangeRate":-0.013888},{"month":5,"riseRate":0.2,"avgChangeRate":-0.123071},{"month":6,"riseRate":0.5625,"avgChangeRate":0.053114},{"month":7,"riseRate":0.4375,"avgChangeRate":0.055385},{"month":8,"riseRate":0.5625,"avgChangeRate":0.025363},{"month":9,"riseRate":0.375,"avgChangeRate":0.027376},{"month":10,"riseRate":0.4375,"avgChangeRate":0.043001},{"month":11,"riseRate":0.4375,"avgChangeRate":0.046811},{"month":12,"riseRate":0.4375,"avgChangeRate":0.056932}],"exchange":"NASDAQ","name":"CorMedix Inc.","nameEN":"CorMedix Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CorMedix Inc.,CRMD,CorMedix Inc.股票,CorMedix Inc.股票老虎,CorMedix Inc.股票老虎国际,CorMedix Inc.行情,CorMedix Inc.股票行情,CorMedix Inc.股价,CorMedix Inc.股市,CorMedix Inc.股票价格,CorMedix Inc.股票交易,CorMedix Inc.股票购买,CorMedix Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction